- Internally-developed anti-PD-1 antibody tislelizumab and BTK inhibitor BRUKINSA® (zanubrutinib) are included in the NRDL in a total of four approved indications
- XGEVA® (denosumab) from BeiGene’s strategic collaboration with Amgen is included in one approved indication
- Company to host investor conference call and webcast on Monday, December 28 at 7:00 p.m. EST. A live webcast of the conference call can be accessed from the investors section of BeiGene’s website at http://ir.beigene.com or http://hkexir.beigene.com. An archived replay will be available two hours after the event for 90 days.
- https://www.biospace.com/article/releases/beigene-announces-inclusion-of-three-innovative-oncology-products-in-china-national-reimbursement-drug-list-nrdl-/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.